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Abstract
Background:  Mechanicosensory mechanisms regulate cell differentiation during lung
organogenesis. We have previously demonstrated that cystic fibrosis transmembrane conductance
regulator (CFTR) was integral to stretch-induced growth and development and that transient
expression of antisense-CFTR (ASCFTR) had negative effects on lung structure and function. In this
study, we examined adult alveolar type II (ATII) cell phenotype after transient knock down of CFTR
by adenovirus-directed in utero expression of ASCFTR in the fetal lung.
Results: In comparison to (reporter gene-treated) Controls, ASCFTR-treated adult rat lungs
showed elevated phosphatidylcholine (PC) levels in the large but not in the small aggregates of
alveolar surfactant. The lung mRNA levels for SP-A and SP-B were lower in the ASCFTR rats. The
basal PC secretion in ATII cells was similar in the two groups. However, compared to Control ATII
cells, the cells in ASCFTR group showed higher PC secretion with ATP or phorbol myristate
acetate. The cell PC pool was also larger in the ASCFTR group. Thus, the increased surfactant
secretion in ATII cells could cause higher PC levels in large aggregates of surfactant. In freshly
isolated ATII cells, the expression of surfactant proteins was unchanged, suggesting that the lungs
of ASCFTR rats contained fewer ATII cells. Gene array analysis of RNA of freshly isolated ATII cells
from these lungs showed altered expression of several genes including elevated expression of two
calcium-related genes, Ca2+-ATPase and calcium-calmodulin kinase kinase1 (CaMkk1), which was
confirmed by real-time PCR. Western blot analysis showed increased expression of calmodulin
kinase I, which is activated following phosphorylation by CaMkk1. Although increased expression
of calcium regulating genes would argue in favor of Ca2+-dependent mechanisms increasing
surfactant secretion, we cannot exclude contribution of alternate mechanisms because of other
phenotypic changes in ATII cells of the ASCFTR group.
Conclusion: Developmental changes due to transient disruption of CFTR in fetal lung reflect in
altered ATII cell phenotype in the adult life.
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Background
Cell development and differentiation in the fetal lung are
regulated by mechanical, physiologic, and biochemical
factors [1]. The markers for peripheral lung development
include maturation of alveolar type II (ATII) cells as evi-
denced by the appearance of lamellar bodies and
increased expression of surfactant phospholipids and pro-
teins, and transformation of ATII cells into type I cells [2-
4]. Previously studies have demonstrated that cystic fibro-
sis transmembrane conductance regulator (CFTR) mRNA
and protein are expressed in adult ATII cells and that the
CFTR-like chloride channel is functional [5-7]. However,
its role in development of fetal ATII cells is unclear. One
possible mechanism is that CFTR-mediated chloride
secretion in the fetal lung epithelium can concomitantly
increase fluid secretion and lung fluid volume [7,8]. Lung
distention due to increased fluid secretion and fluid vol-
ume can accelerate peripheral lung development and ATII
cell maturation as demonstrated in tracheal occlusion
studies [9,10]. Conversely, decreased lung volume in con-
genital diaphragmatic hernia can result in impaired lung
growth and differentiation [9,11]. Multiple studies utiliz-
ing in utero gene transfer and transient over-expression of
CFTR have shown increased fetal lung volume, and accel-
erated maturation of ATII cells [11-14].
Mutations of CFTR gene have been associated with Cystic
Fibrosis (CF); however, the mechanism for its direct par-
ticipation in the disease pathology remains unclear [1].
CFTR is found in the epithelial cells of many organs
including the lung. The crucial role of CFTR in the cellular
development and cell differentiation in the lung has
become somewhat clear with studies involving in utero
gene transfer technology developed by Larson and Cohen
[13,15,16]. This technique circumvents the early develop-
mental role of CFTR and allows investigations into the
role of CFTR (or any other gene) in a stage-specific man-
ner in accessible organs. Using this technique, recent stud-
ies have shown a role of CFTR in fetal lung development
because its over-expression increases mechanical stretch
in the lung [12].
Pulmonary surfactant is essential for the biophysical and
immunologic integrity of the lungs and for maintenance
of the patency of small airways and alveoli [17-19]. Phos-
phatidylcholine (PC) is the major phospholipid and prin-
cipal surface-active constituent in pulmonary surfactant.
Four surfactant proteins – SP-A, SP-B, SP-C, and SP-D –
are present, each of which plays a role in lowering of the
surface tension or in the innate host-defense mechanisms
in the lung. Several investigations have used differential
centrifugation of the bronchoalveolar lavage (BAL) fluid
for further fractionation into large aggregates (LA) and
small aggregates (SA) of lung surfactant [20]. The LA frac-
tion contains multilamellar structures, the tubular mye-
lin, surfactant phospholipids and most of the SP-A, SP-B
and SP-C proteins. It represents the newly secreted sur-
face-active form of alveolar surfactant, which is capable of
reducing the surface tension and is the precursor for the
lighter SA fraction of lung surfactant and contains mostly
small vesicles, surfactant phospholipids and small
amounts of SP-A, SP-B and SP-C proteins [20-22].
The secretion of surfactant phospholipids in ATII cells
occurs by exocytosis of lamellar bodies [23,24]. Surfactant
homeostasis is under feedback regulation by surfactant
proteins which increase surfactant clearance and uptake
by ATII cells [23,25-27]. Different physiological, bio-
chemical and pharmacological factors also regulate sur-
factant secretion through specific cell surface receptors
like β-adrenergic, purinergic and endothelin receptors or
by directly affecting second messenger like calcium,
cAMP, and diacylglycerol [23,28,29]. Although the
expression of surfactant phospholipids and proteins
increases with lung and ATII cell maturation, temporal
expression of each constituent may be independently reg-
ulated [30-32].
Adenovirus-mediated transfer of genes into cells has been
used in several cell types including some hard to transfect
cells like ATII cells. Our group has previously used this
technique for in utero transfer of CFTR constructs and
demonstrated gene-specific effects on lung development
in various species [4,11-13,16,33-37]. The expression of
adenovirus-mediated transferred gene was transient and
lasted only 48–72 h post-transfer [13,34]. In our previous
studies, we have repeatedly shown lack of inflammation
in control animals that were treated with adenovirus-
reporter gene constructs confirming our interpretations
that the effects were due to the target gene transfer into
presumably pluripotent cells in the developing lung. Our
previous study employing in utero treatment with anti-
sense-CFTR (ASCFTR) construct showed airway thicken-
ing with collagen deposits in the small and large airways
and increased airway reactivity to acetylcholine in 100
days old rats [34].
This study was undertaken to determine if transient dis-
ruption of lung organogenesis can result in altered pheno-
type of ATII cells in the adult lung. Because our previous
studies suggested accelerated maturation of ATII cells with
transient over expression of CFTR in fetal lung [13], we
postulated that a transient knock down of CFTR in fetal
lung would cause delayed or erratic development and
cause persistent effects in ATII cell phenotype. We now
show that a similar approach utilizing transient in utero
disruption of CFTR caused changes in surfactant protein
expression and in the alveolar surfactant phospholipid
pool in lungs of adult ASCFTR rats. Studies with isolated
adult lung ATII cells from these animals also showedBMC Cell Biology 2009, 10:24 http://www.biomedcentral.com/1471-2121/10/24
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changes in surfactant secretion suggesting altered cell phe-
notype. The latter was also confirmed by gene array anal-
ysis of RNA from freshly isolated ATII cells, which showed
altered expression of several genes including calcium reg-
ulating genes, the Ca2+-transporting ATPase (Atp2c2, also
known as Spca2) and calcium-dependent calmodulin
kinase kinase1 (CaMkk1). The latter is known to cause
phosphorylation and stimulation of calcium-calmodulin
kinase I (CaMKI) [38,39]. The expression levels of CaMKI,
which also regulates surfactant secretion in ATII cells [40],
were elevated in ATII cells from ASCFTR rats. Thus, tran-
sient in utero knock down of CFTR causes changes in lung
development which is reflected in altered ATII cell pheno-
type in the adult lung.
Results
Studies in the lung tissue
Airways & Parenchymal changes
The model of in utero gene treatment has been used in our
laboratories for several investigations to determine the
role of CFTR in fetal lung development. This model utiliz-
ing intra-amniotic delivery of target gene is designed for
gestation periods when sufficient fluid is present in the
amniotic sac for fluid injection. Although transgene
expression decreases rapidly in the 30 days post-transfer
[41], it is noteworthy that the CFTR knock down in these
animals lasts only for 48–72 h post-transfer [13,34]. In
our study, we observed structural changes in the 3-month
old ASCFTR rats as evidenced by peribronchial thickening
with multicellular airway epithelia suggesting thickening
of airways (figures 1B and 1D) in comparison to the con-
trols (figures 1A and 1C). A previous study from our group
had noticed similar changes including interstitial lung
fibrosis in 100 days old rats that were treated with ASCFTR
in utero [34]. Lung pathology in human Cystic Fibrosis
(CF) and CFTR knock down animal models is character-
ized by chronic inflammatory changes [36], which pre-
clude a single causative factor for CF. Nevertheless, lung
pathology and inflammation is observed in young CF
patients without any overt bacterial infections [reviewed
in [42]]. Previous studies from our group have indicated
lung inflammation in rats that were treated with the
ASCFTR constructs in utero. In the current study also, we
observed some cell infiltrates in lung parenchyma of
ASCFTR (figures 1B and 1D), but not in the Control rats
(figures 1A and 1C). In the present study, we did not eval-
uate neutrophil infiltration and resulting inflammation in
the ASCFTR animals. Thus, it is unlikely that the study ani-
mals suffered from chronic bacterial infection even
though the ASCFTR animals (as well as the control ani-
mals) were maintained under normal housing condi-
tions. Thus, this study confirming reproducibility of our
model of in utero gene treatment with ASCFTR was not
extended for additional histological studies.
Surfactant phospholipids
Several studies have evaluated surfactant subfractions of
BAL fluid samples to investigate the in vivo functions of
ATII cells. The LA fraction represents the newly secreted
surfactant which is capable of reducing the surface tension
whereas the SA fraction contains old and inactive sur-
factant components [20-22]. The alveolar surfactant
homeostasis is maintained by different mechanisms
involving secretion and clearance as discussed above. The
BAL fluid of ASCFTR-treated lungs showed higher total PL
and PC contents in the LA fraction of lung surfactant (fig-
ures 2A and 2B). The increase in alveolar surfactant PC in
LA fraction is possibly due to higher secretion, decreased
conversion into SA fraction, or a combination of both.
The SA fraction of BAL fluid showed decreased level of PC
in the ASCFTR-treated group (figure 2C) suggesting
decreased conversion of LA to SA fraction of lung sur-
factant. This was also confirmed by distribution analysis
of total phospholipids and PC that showed decreased pro-
portion of lipids in the SA fraction (Table 1). However, we
cannot exclude the contribution of increased clearance of
SA fraction to overall decrease in the PC pool in SA frac-
tion of lung surfactant in ASCFTR rats.
Surfactant proteins
Like surfactant lipids, surfactant proteins are also synthe-
sized and secreted by ATII cells. Surfactant secretion and
clearance is under regulatory control of surfactant pro-
teins, particularly SP-A, since this most abundant sur-
factant protein plays a major role in surfactant
homeostasis by promoting clearance and inhibiting secre-
tion of lung surfactant [25-27,29]. The SP-A and SP-B
mRNA levels in the lung tissue were lower in lungs of
ASCFTR group compared to Control group (figure 3).
However, western blot analysis of SP-A and SP-B in the LA
fraction of alveolar surfactant and of the lung tissue did
not show any difference between the two groups (not
shown). The decrease in the mRNA levels of these two
proteins in the ASCFTR group can possibly occur because
of decreased ATII cell number in the lungs (see below) or
altered cell function leading to changes in surfactant
homeostasis. The surfactant proteins in the alveolar and
lung compartments could remain unchanged because of
corresponding decreases in the synthesis (as expected
from decreased mRNA) and in the degradation of pro-
teins. This probability would suggest dissociation
between the synthesis and clearance processes for the sur-
factant protein and lipid components. We are unable to
determine if such dissociation is due to immaturity or
pathologic abnormality caused by a transient knock down
of CFTR in the fetal lung.
Although not significantly decreased, the SP-C mRNA in
the ASCFTR group also showed a decreasing trend in com-
parison to the Control group. Since SP-C is a marker forBMC Cell Biology 2009, 10:24 http://www.biomedcentral.com/1471-2121/10/24
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ATII cells, this pattern for SP-C mRNA could be a reflec-
tion of decreased number of ATII cells. Immuno-staining
of lung sections for proSP-C showed that fewer cells con-
tained proSP-C in the ASCFTR lungs in comparison to the
Control lungs (figure 4A). Analysis of five random fields
in each group for fluorescent objects indicated that the
number of proSP-C positive cells was significantly lower
in the ASCFTR group in comparison to the controls (figure
4B).
Studies in the ATII cells
PC Secretion
The secretion of lung surfactant in ATII cells is a vital cell
function, since its disruption would result in deficiency of
alveolar surfactant and lead to respiratory distress. There-
fore, evaluation of basal and stimulated secretion of sur-
factant PC can be used to test ATII cell function and
establish phenotypic changes in the cells [23,43]. During
the 2 h incubation, the basal PC secretion in ATII cells was
similar in both groups (Control, 1.05 ± 0.19% and,
ASCFTR, 0.82 ± 0.11%. n = 6 each, P > 0.05). The secreta-
gogue-stimulated secretion was expressed as percent of
basal secretion. The ATP-stimulated secretion was higher
by about 30%. Similarly, the phorbol myristate acetate
(PMA)-stimulated secretion was higher in the ASCFTR
cells in comparison to the Control cells (figure 5). In order
to determine if the secretion changes were accompanied
by change in the cell PC pool, we measured equilibrium
labeling (a measure of cell PC pool) of cells in these exper-
iments. The labeling of cellular PC was higher by 30% in
In utero treatment with ASCFTR causes structural changes in the lung of adult rats Figure 1
In utero treatment with ASCFTR causes structural changes in the lung of adult rats. Lung sections from 3 months 
old rats were stained with hematoxylin and eosin and viewed by light microscopy. Frequent areas showing airway thickening 
and multilayered epithelia (filled arrows) were observed in the ASCFTR rat lungs (B and D), while the control lungs showed 
normal architecture (A and C). Some alveolar areas (open arrows) with cellular infiltration were also observed in the 
ASCFTR rats. Original magnification, A and B ×100; C and D ×200BMC Cell Biology 2009, 10:24 http://www.biomedcentral.com/1471-2121/10/24
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the ASCFTR cells when compared with the Control cells
(figure 6). Since equivalent numbers of cells were plated
for both groups, the results suggest higher PC mass and
consequently higher absolute secretion of PC on per cell
basis. Extrapolation of these findings to the in vivo func-
tion of ATII cells suggests that the increased pool of cell PC
in the ASCFTR treated lungs could result in greater pool of
PC in the alveolar surfactant.
Surfactant proteins
Since evaluation of surfactant protein expression in lung
tissue showed lower levels of SP-A and SP-B mRNA in the
ASCFTR treated group (figure 3), we also measured the
mRNA levels of these genes in the freshly isolated ATII
cells (figure 7). For real-time RT-PCR analysis, control and
ASCFTR cell RNA samples were paired for the day of cell
preparation. The SP-A, SP-B and SP-C mRNA levels in
freshly isolated ATII cells were similar in the two groups.
Combining these results and the results from PC secretion
experiments, our study suggests lack of coordination
between the secretory function of surfactant phospholip-
ids, the PC pool and the surfactant proteins mRNA levels
suggesting altered ATII cell phenotype. The discrepancy in
the surfactant proteins expression in the lung tissue (fig-
ure 3) and isolated ATII cells (figure 7), and the decreased
immuno-staining for proSP-C in ASCFTR lungs (figure 4)
suggest that lungs of ASCFTR rats contain fewer ATII cells
in comparison to the Control lungs.
Calmodulin kinase and Calcium Regulating Genes
To obtain additional evidence for phenotypic changes in
ATII cells, the total RNA from freshly isolated ATII cells
was evaluated for altered gene expression by Microarray
analysis using Affymetrix GeneChip®. Gene array analysis
of 30,000 genes on the chip returned 4067 genes above
the background level. The heat map demonstrating signif-
icantly altered expression of 101 genes in adult ATII cells
as a result of transient in utero knock down of CFTR (P <
0.001 or better for all) is depicted in figure 8A. Forty genes
showed at least 50% decrease and 22 genes showed
greater than 2-fold increase in comparison to the Con-
trols. These included Atp2c2 and CaMkk1 genes that reg-
ulate calcium transport or calcium related processes,
respectively. Because ASCFTR cells demonstrated
increased secretion of lung surfactant upon stimulation
with secretagogues, we further verified altered expression
of these two genes by real-time PCR. The expressions of
CaMkk1 and Atp2c2 in the ASCFTR group were 281 ±
53% and 216 ± 14% of the Control group (figure 8B).
CaMkk1 can phosphorylate CaMKI and increase its activ-
ity several folds [44]. Western blot analysis showed highly
elevated expression of CaMKI (figure 8C). Since Ca2+ is
required for stimulated secretion of surfactant [24,45,46],
increased expression of proteins regulating intracellular
Ca2+ levels and Ca2+-dependent protein kinase activity
could be one possible mechanism for increased surfactant
secretion. However, additional or alternate mechanisms
like increased receptor density for purinergic receptors
(for ATP effect) and/or increased PKC activity (for both
ATP and PMA effects) could also play a role in increasing
surfactant secretion.
Discussion
The molecular basis of fetal lung development is believed
to be under genetic and hormonal control [47,48]. Molec-
ular cloning studies have shown that CFTR gene expres-
sion is regulated during lung development [49]. In
addition, changes in CFTR expression can regulate fetal
lung development [33]. We have previously shown that
transient CFTR over-expression in the fetal lung following
in utero gene transfer can modulate lung cell differentia-
tion and maturation [13]. The in utero gene transfer is a
useful tool to evaluate the developmental role of a gene in
lung development [15,16]. Previous studies have demon-
strated that the gene knock down after in utero transfection
with antisense CFTR is transient [13,34]. The hypothesis is
that this technique aims to alter gene expression in undif-
ferentiated multipotent cells lining the developing air-
ways. The infection efficiency or the cell types infected
cannot be determined in these studies because of low
virus dose resulting in low infectivity. Also, such determi-
nation would not be of significance because of the ongo-
ing cell differentiation and proliferation during lung
development. Although somewhat invasive, the fetuses
treated with the control gene show normal differentiation
and growth [14]. Our current study demonstrates that
transient in utero knock down of CFTR with antisense con-
structs can alter the ATII cell phenotype in the adult ani-
mals suggesting persistent changes in cell phenotype
possibly due to altered lung development.
The transient perturbations in gene expression due to
ASCFTR treatment in the fetal lung were associated with
Table 1: Percent distribution of phospholipids and 
phosphatidylcholine in the large and small aggregates of alveolar 
surfactant
Control ASCFTR P value
Phospholipid
Large Aggregates 25.7 ± 4.0% 48.6 ± 6.7% <0.05
Small Aggregates 74.3 ± 4.0% 51.4 ± 6.7% <0.05
Phosphatidylcholine
Large Aggregates 16.2 ± 2.5% 33.2 ± 4.7% >0.05
Small Aggregates 83.8 ± 2.5% 66.8 ± 4.7% >0.05
Relative distribution of total phospholipids and phosphatidylcholine 
between the large and small aggregates of alveolar surfactant is 
expressed as percent distribution. Results are mean ± SE of 7 animals 
in the control and ASCFTR groups. Results are significantly different 
at P < 0.05.BMC Cell Biology 2009, 10:24 http://www.biomedcentral.com/1471-2121/10/24
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Phospholipid and Phosphatidylcholine in large and small aggregates of alveolar surfactant Figure 2
Phospholipid and Phosphatidylcholine in large and small aggregates of alveolar surfactant. Bronchoalveolar lavage 
fluid from control and ASCFTR animals was centrifuged to obtain the large and small aggregate fractions of alveolar surfactant. 
Lipid extracts were evaluated for total phospholipids (A) and phosphatidylcholine (PC) (B). Results are mean ± SE of 7 animals 
in each group and are expressed as total μg lipid in lung. Total phospholipids and PC were higher in the ASCFTR rats. * P < 
0.05. The mass of phospholipid was calculated by assuming that phospholipids phosphorous comprised 4% of the lipid mass. 
(C) The PC levels were lower in the small aggregate (SA) fraction in the ASCFTR rats in comparison to controls (* P < 0.05, n 
= 7, each).
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altered surfactant status in the adult lung as suggested by
increased alveolar pool size of surfactant lipids (figures 2A
and 2B) without affecting the surfactant protein levels.
Similar results have been reported for surfactant status in
CF mice or patients [18,30,50]. Non-infected CF mice
showed increased phospholipids pool in large aggregates
without accompanying change in the SP-A levels [30].
Also, the alveolar surfactant phospholipid composition
and function are altered in CF patients [18,30,50]. Our
study suggests that the increase in large aggregates could
result from higher surfactant secretion rather than
decreased clearance of inactive components in the small
aggregates (figure 2C). The size of alveolar surfactant pool
is maintained by secretion and clearance processes which
are coupled in normal lung [23,29]. The uptake of sur-
factant by ATII cells and by macrophages are the main
routes of clearance and only a small portion of surfactant
is cleared by upwards movement along the airways
[23,29]. The increased pool size and increased secretion
would suggest altered surfactant turnover in ASCFTR rat
lungs. Previous studies also suggested altered ATII cell
phenotype in mutant CFTR mice as they showed higher
alveolar phospholipid because of the decreased uptake of
alveolar PC [30,51]. Thus, two different approaches, tran-
sient (this study) and stable knockdown of CFTR [30],
show alterations in ATII cell phenotype albeit in different
processes. Although not directly related to surfactant
metabolism, previous studies with isolated fibroblasts
and platelets from CF patients also showed a change in PC
metabolism since these cells showed increased PC synthe-
sis [52]. The ASCFTR- treated ATII cells also show a larger
cell PC pool (figure 6) and increased PC secretion that
could contribute to increase alveolar pool of lung sur-
factant (figures 2A and 2B). The increase in PC secretion
was observed with both ATP and PMA (figure 5) suggest-
ing that the altered response may involve multiple path-
ways. One of these is likely the PKC-mediated pathway,
since ATP stimulation of purinergic receptors [53,54] and
consequent increases in intracellular Ca2+ and diacylglyc-
erol [28,55] would also stimulate PKC, while PMA
directly stimulates PKC activity to increase surfactant
secretion [24,28,55,56]. The increased expression of
Atp2c2 and of Ca2+-dependent CaMkk1 and CaMKI (fig-
ure 8) would suggest that the Ca2+-dependent surfactant
secretion [24,40,45,46] could be also elevated in ATII cells
in the ASCFTR group. Although deficiency of surfactant
proteins particularly SP-A could explain higher secretion
and content of alveolar PC [25,29], its deficiency in lung
or large aggregates was not observed in spite of decreased
mRNA level in the lung tissue. Our study was not designed
to determine the underlying mechanism of increased
secretion which could occur through several processes
including increased Ca2+-signaling, higher cell affinity to
secretagogues because of increased receptor density,
increased activity of intermediary steps like PKC activa-
tion for regulation of secretion, or more efficient fusion
and exocytosis of lamellar body contents in the ASCFTR
group.
The observations of decreased mRNA levels (figure 3)
without accompanying decreases in SP-A and SP-B pro-
tein levels in the lung tissue of ASCFTR rats also suggest
altered ATII cell phenotype. We cannot determine if disso-
ciation between the transcription and translation proc-
esses contributed to this discrepancy. Because the mRNA
levels of these proteins were not decreased in ATII cells
(figure 7), it is likely that a decrease in the ATII cell
number (figure 4) contributed to the overall decrease in
surfactant protein mRNA in ASCFTR lungs. We suggest
that the observed changes in ATII cell characteristics and
cell number could occur because of developmental and
cell differentiation-related changes. In previous study
[13], developmental and differentiation related changes
with CFTR over-expression possibly contributed to accel-
erated differentiation of fetal lung cells.
The results of transient perturbation in CFTR expression in
the fetus suggest the importance of CFTR in fetal lung
development [16,34]. The mechanisms that modify the
ATII cell phenotype in the adult animal are likely complex
but could be related to early effects of CFTR on expression
Real-time PCR of surfactant-associated protein mRNA  expression in lung Figure 3
Real-time PCR of surfactant-associated protein 
mRNA expression in lung. Lung tissue was stored in the 
RNALater® buffer for extraction of total RNA. Real-time 
PCR was performed for quantification of mRNA levels for 
SP-A, SP-B and SP-C and normalized to the house-keeping 
gene RPL13A. To obtain ratios of normalized mRNA levels 
for each protein for the ASCFTR and control lung, samples 
were paired with respect to the day of sacrifice. The average 
results of triplicate samples are paired and calculated as per-
cent of control. Results are expressed as percent change (in 
comparison to the control) and are mean ± SE of 5 pairs of 
animals for each protein. * The difference was considered 
significant at ≥ 50% decrease.BMC Cell Biology 2009, 10:24 http://www.biomedcentral.com/1471-2121/10/24
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Immuno-staining of lung sections for proSP-C Figure 4
Immuno-staining of lung sections for proSP-C. A. Sections of frozen lungs from Control and ASCFTR rats were probed 
with polyclonal antibodies to proSP-C and then with Cy3-labeled secondary antibodies (red). The cell nuclei were counter-
stained with DAPI (blue). The sections were viewed with a fluorescence microscope and photographed after deconvolusion 
and normalization of Cy3 fluorescence intensity to the same range of pixel density for the Control and ASCFTR specimens. B. 
A comparison of fluorescent object count between the Control and ASCFTR specimens showed a significant decrease in 
proSP-C positive cells (ATII cells) in the ASCFTR group in comparison to the Control group.
A 
B BMC Cell Biology 2009, 10:24 http://www.biomedcentral.com/1471-2121/10/24
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of smooth muscle function-related genes and on mechan-
ical stretch in the fetal lung [9-11]. Previous study has sug-
gested that in utero over-expression of CFTR increases
stretch in the fetal lung apparently through altered expres-
sion of myosin light chain kinase and myosin light chain
phosphorylation [12]. Therefore, we presumed that
decreased mechanical stretch results from CFTR knock
down in the fetal lung that could possibly inhibit matura-
tion of ATII cells [2,3,57]. Our current study of alterations
in ATII cell function with transient knock down of CFTR
gene expression further supports the modification of fetal
lung development and differentiation processes by in
utero gene delivery [13]. The resulting changes, like altered
ATII cell physiology, apparently persist in the adult life of
the animal suggesting that the effects of such interference
in lung development in the fetus could linger for long
periods. Such outcome supports the previously stated pos-
tulate that genetically encoded injury could have immedi-
ate effects even with apparently normal lung function and
appearance [13]. Such a scenario can be seen in CF where
the deleterious pathway begins early in the fetal lung [4].
However, several compensatory mechanisms may func-
tion in CF in an organ-specific manner, since the effects of
global deficiency of CFTR manifest markedly differently
in different organs. Although some of these mechanisms
in the lung may be initiated during the period of in utero
gene disruption in our protocol, extensive studies would
need to be undertaken for such determination.
In summary, this study has shown that in utero transient
disruption of CFTR gene results in lasting phenotypic
change in ATII cell, altered surfactant homeostasis, and
expression of several genes in adult rat ATII cells. The
underlying mechanisms for change in ATII cell function is
unclear but could result from diminished mechanical
stretch in the fetal lung and result in delayed cellular dif-
ferentiation. Further detailed investigations would be
needed to establish if decreased number of ATII cells and
metabolic abnormalities also contribute to altered lung
surfactant homeostasis.
Conclusion
Transient In utero disruption of CFTR can affect adult lung
characteristics suggesting that events in fetal life can have
persistent and long lasting effects in the adult life.
Lung surfactant secretion in alveolar type II cells isolated  from control and ASCFTR rats Figure 5
Lung surfactant secretion in alveolar type II cells iso-
lated from control and ASCFTR rats. Alveolar type II 
cells were isolated from lungs of paired Control and ASCFTR 
rats. The cells were cultured for 20–22 h with [methyl-
3H]choline to label cell phosphatidylcholine (PC). Following 
this culture period, adherent cells were incubated for 2 h 
without (basal secretion) or with addition of 1 mM ATP or 
80 nM phorbol 12-Myristate 13-Acetate (PMA). The basal 
secretion was 1.05 ± 0.19% and 0.82 ± 0.11%, n = 6, in the 
control and ASCFTR cells, respectively (P > 0.05). The ATP 
and PMA-stimulated secretion is expressed as percent of the 
basal secretion. * P < 0.05 in comparison to the Control 
cells.
Phosphatidylcholine pool in alveolar type II cells Figure 6
Phosphatidylcholine pool in alveolar type II cells. Equi-
librium labeling of cell phosphatidylcholine (PC) with [methyl-
3H]choline was used to measure the PC pool in alveolar type 
II cells. The cells were labeled for 20–22 h, as discussed for 
PC secretion studies. The radioactivity in the cell lipids was 
quantified. Results are mean ± SE of 6 separate experiments. 
The PC pool in ASCFTR cells was higher in comparison to 
the control cells. * P < 0.05.BMC Cell Biology 2009, 10:24 http://www.biomedcentral.com/1471-2121/10/24
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Methods
In utero gene transfer
All procedures involving animal experiments were
approved by the Institutional Animal Care Committee.
The in utero gene transfer technique is described previ-
ously [34]. It involves intra-amniotic administration of
constructs containing the gene of interest. For this study,
the adenovirus was constructed from an ATCC plasmid
containing exons 1–6 of cftr cloned into a recombinant
adenovirus in the antisense direction (AdCMVAScftr).
Briefly, timed-pregnant Sprague Dawley rats at 16 days of
gestation were anesthetized by inhalation of 5% isoflu-
rane. Anesthesia was maintained by inhalation of 2% iso-
flurane. A laparotomy was performed, uterine horns were
exposed, and adenoviral particle suspension in Dul-
becco's Modified Essential Medium was injected into
amniotic sac of each fetus using a fine gauge needle. The
injected volume was estimated at 10% of the amniotic
fluid volume and the final concentration of recombinant
adenoviruses was 108 plaque-forming units (pfu)/ml [14].
Control animals were similarly injected with recombinant
adenovirus containing enhanced green fluorescence pro-
tein (EGFP) reporter gene (generous gift of J. Kolls, Uni-
versity of Pittsburgh). We did not use sense-CFTR in the
controls because our previous studies demonstrated that
CFTR over-expression, as would be achieved with the
sense-CFTR, caused morphologic changes in the develop-
ing lung [13]. Because of transient expression of genes, we
injected all littermate fetuses on the same day with either
the control or the ASCFTR construct in separate pregnant
animals. All rats were housed in standard housing condi-
tions in unfiltered cages until normal delivery at term. The
newborn pups were weaned at 21 days of post natal life
and maintained under normal housing conditions.
Type II cell isolation
At 3–4 months of age, adult male rats were used for isola-
tion of alveolar ATII cells. We used the previously pub-
lished protocol [58] as modified by Sen and Chander
[59]. In brief, rats were anesthetized with sodium pento-
barbital (50 mg/kg, intraperitoneal), tracheostomized,
and exsanguinated. The lungs were ventilated and cleared
of residual blood by perfusion through the pulmonary
artery. The lungs were removed, lavaged, and treated
(three times) with intratracheally instilled elastase solu-
tion (3 U/ml) (Worthington, Biochemicals, Freehold, NJ).
The lung lobes were minced on a tissue chopper, sus-
pended in buffer containing DNase, and mixed vigorously
for 2 min in a water bath at 37°C. The free cells in suspen-
sion were sequentially filtered through nylon filters of
decreasing pore size, and centrifuged for 10 min at 300 ×
g. Cells in the pellet were suspended in minimum essen-
tial medium (MEM) and incubated for 1 h at 37°C on
IgG-coated bacteriologic culture dishes. The free cells were
subsequently collected by "panning," centrifuged and sus-
pended in MEM containing 10% fetal bovine serum
(FBS). Acridine orange staining [60] showed that ATII
cells accounted for ~ 90% of the total cells. Aliquots of the
isolated cells were saved for RNA studies and remaining
cells were plated on 35-mm tissue culture plates at a den-
sity of 1.5 × 106 cells in 1.5 ml MEM-10% FBS. Plated cells
were incubated for 20–22 h at 37°C in humidified air
containing 5% CO2. Cells attached to the tissue culture
plates after overnight incubation were >92% ATII cells as
determined by acridine orange staining.
PC Secretion and Equilibrium Labeling of Cell PC
For studies on PC secretion, isolated cells were plated in
MEM containing 10% FBS and 0.5 μCi of [methyl-3H]
choline (Amersham, Arlington Heights, IL) and cultured
for 20–22 h. Following this culture period, the adherent
cells were extensively washed to remove non-adherent
cells, serum proteins and unincorporated radioactivity.
One ml of MEM was added to each plate. Duplicates were
done for each rat. After incubation in 5% CO2 at 37°C for
30 min (equilibration period), one set of plates was
removed and labeled as 'zero' time secretion. To the other
plates 10 μl of ATP or PMA was added to yield final con-
centrations of 1 mM or 80 nM, respectively. Control plates
(basal secretion) received 10 μl of water. The plates were
returned to the incubator for 2 hr. Following incubation,
the media were removed and centrifuged (300 × g for 10
min at 4°C) to pellet any cells that might have detached
Surfactant protein mRNA levels in alveolar type II cells Figure 7
Surfactant protein mRNA levels in alveolar type II 
cells. Real-time PCR using total RNA from freshly isolated 
(uncultured) AT II cells was performed for quantification of 
mRNA levels of SP-A, SP-B and SP-C (n = 6, each). The 
results of triplicate analysis for each sample were paired 
between the control and ASCFTR samples and expressed as 
percentage of control. The mRNA levels (normalized to the 
house keeping gene RPL13A) for all three proteins were sim-
ilar in the two groups. The results were considered signifi-
cant at ≥ 200% (≥ 2-fold) of the Control.BMC Cell Biology 2009, 10:24 http://www.biomedcentral.com/1471-2121/10/24
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Gene array analysis of ATII cell RNA Figure 8
Gene array analysis of ATII cell RNA. Gene expression in adult type II cells isolated from animals that were infected in 
utero with adenovirus containing EGFP (Control) or ASCFTR constructs. A. Heat map for 101 genes in three separate prepa-
rations of type II cells demonstrating altered expression in the ASCFTR group in comparison to the Control group. B. Results 
of real-time PCR analysis of RNA from three separate preparations of freshly isolated type II cells showing enhanced expres-
sion of Ca2+-ATPase and calcium-dependent calmodulin kinase kinase1. Results (mean ± SE, n = 3) are expressed as change in 
threshold cycle for the target gene in comparison to the house keeping gene, RPL13A. A smaller ΔCt value indicates higher 
expression. * P < 0.05 in comparison to corresponding Control group. C. Western blot analysis showing elevated expression 
of calmodulin kinase I (upper panel) relative to house-keeping protein GAPDH (lower panel). The results of real-time PCR and 
Western blot analysis support the findings of Gene array analysis.
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during incubation. These cells were later pooled with
those recovered from the plates. Lipids from both media
and cells were extracted (see below) after addition of
[methyl-14C] dipalmitoyl phosphatidylcholine (DPPC)
(Amersham) and egg PC (Sigma Chemical Co.) as the car-
rier lipid. Radioactivity in lipid extracts was measured in a
liquid scintillation counter. The recovery of [3H]-choline-
labeled phospholipids was corrected using the recovery of
14C-DPPC. Phospholipid secretion was calculated as per-
cent secretion = (DPM in medium lipids × 100)/(DPM in
lipids in medium plus cells). For quantification of PC
mass, ATII cells were incubated with [3H]choline for 20–
22 h and the radioactivity in cell PC was measured after
lipid extraction. Previous studies have shown that the
incorporation of [3H]choline achieves plateau by 16 h of
incubation and does not change thereafter in continued
presence of [3H]choline [59]. At these equilibrium labe-
ling conditions, the radioactivity in cell PC is representa-
tive of cell PC mass.
Lipid extraction and analysis
Lipids were extracted from all samples using chloroform-
methanol system [61]. The extracted lipids were dissolved
in chloroform-methanol (20:1, v/v). Total phospholipids
in the lipid extract were determined by analysis of phos-
pholipid phosphorus (PLPi) following digestion of lipids
in perchloric acid (70–72%) to release inorganic phos-
phorus (Pi) that was measured according to previously
published methods [62,63]. Lipids extracts were analyzed
for PC after separation of phospholipids by thin layer
chromatography (TLC) [64]. Lipids were visualized by
exposing the TLC plates to iodine vapors, and PC was
identified by co-migration of authentic phospholipid
standards [62,63]. The spots containing PC were removed
from the plates and directly processed for digestion of lip-
ids in perchloric acid (see above) and for spectrophoto-
metric determination of the phosphorus content [62].
RNA Extraction and Analyses
Total RNA from samples of freshly isolated ATII cells and
or samples of lung tissue from different cohorts of ani-
mals were extracted using the RNeasy kit (Qiagen, Inc).
The yield and purity of the isolated RNA were determined
by A260 and A280. Gene array analyses of RNA samples
from three separate preparations of freshly isolated ATII
cells were performed at the DNA Microarray Facility at the
Stony Brook University using GeneChip® Rat Genome 230
2.0 array (Affymetrix).
Real-time PCR
The expression of several proteins was measured by quan-
tifying the mRNA levels by real-time PCR. In this study,
we measured the mRNA levels for surfactant proteins A, B,
and C and for Ca2+-ATPase and CaMkk1 relative to that of
house-keeping gene (RPL13a) encoding for ribosomal pro-
tein L13A, which is a structural component of 60S ribos-
omal subunit. In our previous studies, we had observed
large variations in the expression of GAPDH during fetal
lung development, while RPL13A was more stable. The
RT-PCR primer sets for the target and housekeeping genes
(RPL13a) were obtained from commercial source (Superar-
ray, Inc, Fredrick, MD). Triplicates of a 20 μl reaction mix-
tures containing 20 ng of RNA were analyzed for each
surfactant protein and averaged. The comparative thresh-
old cycle (Ct) method, also known as the Ct method [65],
was used to calculate changes in mRNA levels according to
the following equation.
ΔΔCt = ΔCtexperimental - ΔCtcontrol
Sample Difference = 2-ΔΔCt
Where, ΔCtexperimental is the Ct value for experimental sam-
ple for the target gene normalized to the endogenous
housekeeping gene and ΔCtcontrol is the Ct value for the
control sample for the same target gene also normalized
to the endogenous housekeeping gene [65]. Control and
experimental animals sacrificed on the same day were
paired for comparison. Results from indicated groups of
control and experimental animals are expressed as mean
± SEM of indicated number of such pairs.
Protein Analysis
Total proteins were extracted from lung tissue samples
using ~ 700 μl of fresh whole cell lysis buffer (PMSF 0.25
mM, EGTA 2 mM, 2 × LSB, protease inhibitor cocktail
(Sigma, St Louis, Mo), 50 mM NaF and phosphatase cock-
tail solutions I and II (Calbiochem, San Diego, CA)). Sam-
ples were sonicated, boiled for 5 min and centrifuged to
obtain soluble proteins in the supernatant fraction for
measurement of total proteins. Protein concentrations
were determined spectrophotometrically using a bovine-
γ-globulin as standard [66]. Chemiluminiscence detection
[67] was used to detect indicated antigen (SP-A, SP-B and
CaMKI) by Western blot analysis using respective primary
antibodies. The rabbit SP-B antibody was raised against
Survanta® (Abbott Laboratories, Abbott Park, IL). This
antibody recognized the precursor and the mature forms
of SP-B in lung tissue and only the mature form in the LA
fraction of alveolar surfactant. The SP-A antibody was
obtained from commercial source (Chemicon Interna-
tional, Temecula, CA). The antibodies for CaMKI were
obtained from Santa Cruz Biotechnology (Santa Cruz,
CA). All primary antibodies were used at a dilution of
1:1000 and appropriate secondary antibodies were used
at a dilution of 1:10,000 or 1:20,000. Equal amounts of
total proteins (or volumes, in case of suspension of LA
fraction) were loaded for each sample and the relative
contents of target proteins were quantified after photo-
imaging of Western blots (Hitachi Genetics Systems,BMC Cell Biology 2009, 10:24 http://www.biomedcentral.com/1471-2121/10/24
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Alameda, CA). Images were acquired by GeneSnap pro-
gram (Syngene, Frederick, MD)
Histochemistry and Immunocytochemistry
Lungs were fixed in methanol-free 4% buffered parafor-
maldehyde, mounted in paraffin, and thin (8 μm) sec-
tions were prepared. Slides were immersed in Histol-Clear
solution (National Diagnostics, Atlanta, GA) to remove
residual paraffin and then rehydrated through a series of
washes with decreasing concentrations of ethanol. After
rinsing in distilled water, slides were stained with hema-
toxylin and eosin (Fisher Scientific Inc) and examined by
standard light microscopy. For immuno-staining for
proSP-C, frozen lung sections were blocked for 1 h with
donkey serum, incubated for 75 min with rabbit antibod-
ies to proSP-C (kind gift of Dr. Jeffery A Whitsett, Univer-
sity of Cincinnati) at 1:500 dilution, washed, and
incubated for 30 min with Cy3-conjugated secondary
antibodies (donkey anti-rabbit, Santa Cruz Biotechnol-
ogy) at 1:500 dilution. The sections were counter-stained
with DAPI and viewed and photographed after deconvo-
lution and normalization of fluorescence to the same
pixel density range for the Control and ASCFTR speci-
mens. Image software SLIDEBOOK was used to capture
images and quantify fluorescence for object count. Five
random fields in the peripheral lung sections were evalu-
ated for fluorescence and compared between the two
groups.
Statistical Methods
All statistics were performed using GraphPad Prism soft-
ware program (GraphPad, San Diego, CA). Unpaired stu-
dent's t test was used to analyze data which were expressed
as the mean ± SEM. Differences were considered signifi-
cant at p < 0.05.
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